<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21582" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Factor XIII</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Malkhassian</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>Kaiser Permanente</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sabir</surname>
            <given-names>Sarah</given-names>
          </name>
          <aff>Rawalpindi Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Malkhassian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Sabir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21582.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Although discovered in 1944, Factor XIII's (FXIII) role as a deficiency disorder became evident in the 1960s upon identifying other clotting factors.<xref ref-type="bibr" rid="article-21582.r1">[1]</xref>&#x000a0;Factor XIII, also referred to as fibrin stabilizing factor, plays a crucial role in the coagulation cascade by enhancing the stability of blood clot formation. The plasma form of Factor XIII is a protein heterodimer composed of A and B subunits expressed by bone marrow and mesenchymal lineage cells. Factor XIII functions as a transglutaminase, catalyzing peptide reactions responsible for cross-linking fibrin mesh. A deficiency can lead to life-threatening issues related to clot stability and hemostasis.<xref ref-type="bibr" rid="article-21582.r2">[2]</xref>.&#x000a0;</p>
      </sec>
      <sec id="article-21582.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Although exceedingly rare, congenital disorders of Factor XIII are associated with significant morbidity and mortality. Most commonly inherited in an autosomal recessive manner, immune or idiopathic causes account for acquired forms.<xref ref-type="bibr" rid="article-21582.r2">[2]</xref>&#x000a0;Factor XIII plays a critical role in normal hemostasis. However, there remains a substantial gap in research regarding its potential involvement in other processes. These processes encompass not only delayed postoperative bleeding but also delayed wound healing, recurrent miscarriages, and angiogenesis, as well as acquired coagulopathy resulting from reduced FXIII levels in the context of COVID-19 and Henoch-Sch&#x000f6;nlein purpura.<xref ref-type="bibr" rid="article-21582.r2">[2]</xref>&#x000a0;Additionally, factor XIII plays a role in immune function by killing bacteria and aiding phagocytosis by macrophages. Linked to inflammation, patients with COPD and a smoking history experience accentuated effects of FXIII.<xref ref-type="bibr" rid="article-21582.r2">[2]</xref>&#x000a0;More research is necessary on the involvement of FXIII in additional physiologic processes.</p>
      </sec>
      <sec id="article-21582.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>In the presence of calcium, thrombin converts Factor XIII from a heterotetrameric proenzyme into a transglutaminase. This transglutaminase catalyzes the intertwining of fibrin monomers and forms connections between &#x003b1;2-antiplasmin and fibrin during the coagulation cascade.<xref ref-type="bibr" rid="article-21582.r3">[3]</xref>&#x000a0;This process serves to strengthen the blood clot.</p>
        <p>FXIII has a plasmatic form and a cellular form carried inside platelet alpha granules. The cellular form consists of identical FXIII-A dimers, distinctive for its catalytic transglutaminase domain. The plasma form is a tetramer consisting of FXIII-A and FXIII-B subunits. FXIII-A contains a sandwich domain, a catalytic domain, an activation peptide, and 2 barrel domains. Ten repetitive domains are the defining characteristic of FXIII-B. To activate the plasma form of factor XIII, thrombin cleaves off the activation peptide of FXIII-A with the help of circulating calcium ions. FXIII-B detaches, and FXIII-A becomes the active transglutaminase involved in fibrin cross-linking and clot stabilization.<xref ref-type="bibr" rid="article-21582.r3">[3]</xref>&#x000a0;FXIII-B is a carrier protein that stabilizes subunit A, binds subunit A to fibrinogen, and helps stop FXIII activation.&#x000a0;</p>
      </sec>
      <sec id="article-21582.s4" sec-type="Function">
        <title>Function</title>
        <p>FXIII is a transglutaminase that forms gamma-glutamyl-lysyl amide cross-linking of fibrin, stabilizing the insoluble clot against shear stress. As a result, it achieves further protection from clot degradation in the coagulation cascade.<xref ref-type="bibr" rid="article-21582.r4">[4]</xref>&#x000a0;Factor XIII also works on &#x003b1;2-antiplasmin to cross-link it with fibrin as part of its additional antifibrinolytic properties.<xref ref-type="bibr" rid="article-21582.r5">[5]</xref>&#x000a0;In the case of deficiency, there is a subsequent breakdown of fibrin mesh and recurrent bleeding after clot formation.&#x000a0;</p>
      </sec>
      <sec id="article-21582.s5" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Hemostasis is the body's way of preventing blood loss. The three main stages of hemostasis are vasoconstriction, platelet plug formation, and blood clotting. Within a clot, fibrin mesh strengthening occurs with the aid of Factor XIII, mainly by keeping the platelet plug together. The intrinsic and extrinsic pathways feed into the common pathway during clot formation. The common pathway involves thrombin-catalyzed cleavage of fibrinogen into fibrin, forming a mesh that strengthens the platelet plug. Subsequently, Factor XIII covalently bonds to fibrin to support fibrin's interaction with the platelets further and prevent the clot's dissolution. Clot retraction, which usually occurs a day after the initial clot formation, involves disruption of Factor XIII cross-links and fibrinolysis.<xref ref-type="bibr" rid="article-21582.r6">[6]</xref></p>
      </sec>
      <sec id="article-21582.s6" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>Testing for FXIII deficiency is warranted when general hematology labs show no abnormality of PT, aPTT, INR, and bleeding time in the presence of delayed detachment and bleeding of the umbilical stump, hemorrhage, hemarthrosis, or hematomas. These findings indicate a defect in clot stabilization or fibrinolysis, particularly after trauma or surgical procedures.<xref ref-type="bibr" rid="article-21582.r7">[7]</xref></p>
        <p>In the past, the initial testing for suspected FXIII deficiency involved conducting a clot solubility test. During this procedure, healthcare professionals placed the patient's anticoagulated blood specimen in a centrifuge, where calcium chloride induces plasma clot formation. Subsequently, the formed clot is suspended in 5M urea or 1% monochloroacetic acid solutions and incubated at either 37 &#x000ba;C or room temperature.<xref ref-type="bibr" rid="article-21582.r8">[8]</xref><xref ref-type="bibr" rid="article-21582.r9">[9]</xref>&#x000a0;The healthcare provider then regularly assesses the clot to observe for dissolution. Urea can break down the hydrogen bonds of the early clot but not the covalent bonds created by FXIII. Hypofibrinogenemia and dysfibrinogenemia will result in false-positive results. Urea is more specific, while monochloroacetic acid is more sensitive. In patients with FXIII levels &#x0003c;1%, the clots will dissolve.&#x000a0;The clot solubility test is limited to detecting patients with severe FXIII deficiency and is not recommended as the initial diagnostic test if possible. Although not deemed sensitive, some labs still favor clot solubility due to its simplicity.</p>
        <p>Ammonia is released during the transglutaminase reaction. Another testing mechanism is to measure FXIII activity by automatic ammonia release assay, which involves using ammonia as an indirect measurement of transglutaminase activity.&#x000a0;</p>
        <p>The International Society for Thrombosis and Hemostasis recommends beginning with an FXIII activity level followed by an FXIII antigen level if the FXIII activity levels are low.<xref ref-type="bibr" rid="article-21582.r6">[6]</xref><xref ref-type="bibr" rid="article-21582.r8">[8]</xref>&#x000a0;Factor XIII antigen levels will help differentiate acquired from congenital forms of FXIII deficiency. A mixing study then helps to determine the presence of an FXIII inhibitor. If an inhibitor to FXIII is suspected, clot-based inhibitor assays can only detect neutralizing antibodies. Binding assays, like the sodium-dodecyl sulfate-polyacrylamide ( SDS-PAGE), are necessary to determine the presence of non-neutralizing antibodies.<xref ref-type="bibr" rid="article-21582.r9">[9]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-21582.s7" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The two forms of FXIII deficiency are congenital and acquired.</p>
        <p>
<bold>Congenital Factor XIII Deficiency</bold>
</p>
        <p>Congenital FXIII deficiency is a rare autosomal recessive bleeding disorder. The cause of congenital factor XIII deficiency is a genetic mutation in subunit A of FXIII. Heterozygotes will likely show no symptoms. Homozygotes may present with spontaneous or provoked bleeding in the CNS, joints, or during surgery. Other possible indicators include recurrent pregnancy loss, heavy menstrual bleeding, and delayed detachment or bleeding of the umbilical cord. Due to consanguinuity, patients in Iran have a high rate of rare bleeding disorders, especially FXIII deficiency. While the ideal diagnostic method begins with factor activity measurement, the cost and small number of patients make these tests unavailable in many parts of the world. Patients undergo a PT, aPTT, INR, platelet count, and bleeding time first. If those are normal, then a clot solubility test is next. Molecular diagnosis is not available in many parts of the world. As aforementioned, severe, life-threatening bleeding is often the characteristic clinical presentation.<xref ref-type="bibr" rid="article-21582.r10">[10]</xref>&#x000a0;The prevalence of congenital FXIII deficiency in the general population is 1 per 2 million. Worldwide, FXIII deficiency is most prevalent in the Khash region of southeastern Iran.</p>
        <p>
<bold>Acquired Factor XIII Deficiency</bold>
</p>
        <p>Causes of acquired FXIII deficiency include immune-mediated inhibition, nonimmune FXIII heightened consumption,&#x000a0;and lack of synthesis. Acquired deficiency can be due to idiopathic causes, autoimmune diseases like lupus, and malignant conditions.<xref ref-type="bibr" rid="article-21582.r11">[11]</xref><xref ref-type="bibr" rid="article-21582.r12">[12]</xref>&#x000a0;Researchers have identified autoantibodies that inhibit the cross-linking of fibrin monomers.<xref ref-type="bibr" rid="article-21582.r13">[13]</xref>&#x000a0;Anti-IL6 receptor antibody treatment, like that received by patients with rheumatoid arthritis, has been shown to reduce FXIII activity.<xref ref-type="bibr" rid="article-21582.r14">[14]</xref>&#x000a0;The exact mechanism is unclear, but researchers believe&#x000a0;suppressed FXIII-A expression is the cause.</p>
        <p>The most common cause of death associated with FXIII deficiency is hemorrhage, often intracranial. Due to the rarity of acquired FXIII deficiencies, extensive literature and analytical information are lacking. As research continues to evolve, there have been reports of acquired deficiency in several medical conditions, such as stroke, IBD, liver cirrhosis, and disseminated intravascular coagulation. Factor levels in these medical conditions can drop by 20% to 70% through consumption of FXIII or decreased synthesis.<xref ref-type="bibr" rid="article-21582.r15">[15]</xref></p>
      </sec>
      <sec id="article-21582.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The transglutaminase activity of FXIII is involved in wound healing, embryo and uterus interactions, angiogenesis, and bone extracellular matrix stabilization.<xref ref-type="bibr" rid="article-21582.r5">[5]</xref>&#x000a0;Deficiency of fibrinogen and FXIII can result in recurrent pregnancy loss, indicating their importance in placental stability.<xref ref-type="bibr" rid="article-21582.r12">[12]</xref></p>
        <p>While intracranial hemorrhages are the most common overall cause of death, delayed umbilical cord bleeding, seen in up to 80% of neonates, may be the earliest presenting symptom of Factor XIII deficiency. Other common manifestations of FXIII deficiency are bruising, hematomas, muscle bleeds, and delayed post-surgical bleeding.</p>
        <p>Common clinical signs of coagulation factor deficiencies include mucosal bleeding, bleeding before and after medical procedures, and hemorrhagic diathesis. Fairly specific to low levels of Factor XIII and Factor X and afibrinogenemia, more severe signs include intracranial bleeding and hemarthroses.<xref ref-type="bibr" rid="article-21582.r16">[16]</xref>&#x000a0;</p>
        <p>With the current advancement in treatment for rare factor deficiencies, acutely presenting FXIII-related hemorrhage treatment includes the administration of FXIII concentrates to stop blood loss. Prednisolone and cyclophosphamide combat anti-FXIII antibodies.<xref ref-type="bibr" rid="article-21582.r17">[17]</xref>&#x000a0;Plasma exchange can be beneficial in the short-term management of FXIII inhibitors.<xref ref-type="bibr" rid="article-21582.r18">[18]</xref>&#x000a0;Long-term prophylaxis includes platelet-derived or recombinant FXIII along with cryoprecipitate. The plasma half-life for FXIII is between 11 and 14 days, so regular administration of blood products is often necessary for long-term care.<xref ref-type="bibr" rid="article-21582.r19">[19]</xref>&#x000a0;Women with FXIII deficiency can experience recurrent miscarriages and menorrhagia, while in men, fertility can be affected. Oral contraceptives or antifibrinolytics can help manage menorrhagia.<xref ref-type="bibr" rid="article-21582.r20">[20]</xref></p>
        <p>Other biological functions of factor XIII are under consideration beyond a "fibrin stabilizing factor."&#x000a0;</p>
      </sec>
      <sec id="article-21582.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21582&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21582">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21582/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21582">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21582.s10">
        <title>References</title>
        <ref id="article-21582.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chern</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mapping the quality of prenatal and postnatal care and demographic differences on child mortality in 26 low to middle-income countries.</article-title>
            <source>World J Pediatr</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>835</fpage>
            <page-range>835-850</page-range>
            <pub-id pub-id-type="pmid">36705781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mutch</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Let's cross-link: diverse functions of the promiscuous cellular transglutaminase factor&#x000a0;XIII-A.</article-title>
            <source>J Thromb Haemost</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-30</page-range>
            <pub-id pub-id-type="pmid">30489000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kom&#x000e1;romi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bagoly</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Muszbek</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Factor XIII: novel structural and functional aspects.</article-title>
            <source>J Thromb Haemost</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-20</page-range>
            <pub-id pub-id-type="pmid">20880254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durda</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wolberg</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kerlin</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>State of the art in factor XIII laboratory assessment.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>700</fpage>
            <page-range>700-704</page-range>
            <pub-id pub-id-type="pmid">30087086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Advances of Coagulation Factor XIII.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2017</year>
            <month>Jan</month>
            <day>20</day>
            <volume>130</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-223</page-range>
            <pub-id pub-id-type="pmid">28091415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muszbek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Katona</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Ker&#x000e9;nyi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Factor XIII.</article-title>
            <source>Methods Mol Biol</source>
            <year>2017</year>
            <volume>1646</volume>
            <fpage>277</fpage>
            <page-range>277-293</page-range>
            <pub-id pub-id-type="pmid">28804836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayward</surname>
                <given-names>CPM</given-names>
              </name>
            </person-group>
            <article-title>How I investigate for bleeding disorders.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2018</year>
            <month>May</month>
            <volume>40 Suppl 1</volume>
            <fpage>6</fpage>
            <page-range>6-14</page-range>
            <pub-id pub-id-type="pmid">29741250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorgalaleh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabibian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tavasoli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gheidishahran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shamsizadeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience.</article-title>
            <source>Lab Med</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>220</fpage>
            <page-range>220-6</page-range>
            <pub-id pub-id-type="pmid">27346867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dufner</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Marbet</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>[Factor XIII in man: a review].</article-title>
            <source>Hamostaseologie</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-9</page-range>
            <pub-id pub-id-type="pmid">12193980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorgalaleh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alavi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Tabibian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moradi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bamedi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jalalvand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shamsizadeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.</article-title>
            <source>Hematology</source>
            <year>2017</year>
            <month>May</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>224</fpage>
            <page-range>224-230</page-range>
            <pub-id pub-id-type="pmid">27894217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yan</surname>
                <given-names>MTS</given-names>
              </name>
              <name>
                <surname>Rydz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Goodyear</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sholzberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acquired factor XIII deficiency: A review.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>724</fpage>
            <page-range>724-730</page-range>
            <pub-id pub-id-type="pmid">30446212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshehri</surname>
                <given-names>FSM</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mutch</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Mar</month>
            <day>17</day>
            <volume>22</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">33802692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franchini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frattini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonfanti</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acquired FXIII inhibitors: a systematic review.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-14</page-range>
            <pub-id pub-id-type="pmid">23065324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mokuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tokunaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishitoku</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masumoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling.</article-title>
            <source>Inflamm Regen</source>
            <year>2023</year>
            <month>Jan</month>
            <day>06</day>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">36609460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tahlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>138</volume>
            <issue>2</issue>
            <fpage>278</fpage>
            <page-range>278-81</page-range>
            <pub-id pub-id-type="pmid">24476525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menegatti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Treatment of rare factor deficiencies other than hemophilia.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Jan</month>
            <day>31</day>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>415</fpage>
            <page-range>415-424</page-range>
            <pub-id pub-id-type="pmid">30559262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichinose</surname>
                <given-names>A</given-names>
              </name>
              <collab>Japanese Collaborative Research Group on AH13</collab>
            </person-group>
            <article-title>Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients.</article-title>
            <source>Blood Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">27542511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bodine</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Gooley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Plapp</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Perioperative therapeutic plasma exchange in a patient with rare Factor XIII inhibitor.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>103654</fpage>
            <pub-id pub-id-type="pmid">36775674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Management of rare coagulation disorders in 2018.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>705</fpage>
            <page-range>705-712</page-range>
            <pub-id pub-id-type="pmid">30392819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21582.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nugent</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Factor XIII deficiency.</article-title>
            <source>Haemophilia</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1190</fpage>
            <page-range>1190-200</page-range>
            <pub-id pub-id-type="pmid">19141159</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
